CLOSE
CLOSE
https://www.sikich.com

The Future of Drug Commercialization: Embracing Technology for Success

Navigating the financial hurdles of drug development has become more daunting than ever, with the average cost to bring a pharmaceutical product to market now surpassing a staggering $2 billion USD, according to Deloitte. However, despite such substantial investments, over a third of new launches in the United States fail to meet expectations. In order to combat this trend, many pharmaceutical companies are turning to technology to streamline the drug commercialization process.

Let’s explore how technology is reshaping the landscape of drug commercialization, paving the way for a brighter future.

The Power of Data in Driving Decisions

Imagine having a crystal ball that could predict the success of a drug launch with uncanny accuracy. Well, in a way, data serves as that crystal ball in the pharmaceutical industry. Deloitte’s study reveals that a staggering 36% of drugs launched between 2012 and 2017 missed their launch forecasts, with half of these failures attributed to limited market access.

Leveraging data analytics can provide valuable insights into market trends, patient demographics, and competitor strategies, allowing pharmaceutical companies to make informed decisions.

For instance, data analytics can help identify target patient populations, optimize pricing strategies, and inform marketing campaigns. Ultimately, harnessing the power of data allows companies to make informed decisions that increase the likelihood of a successful drug launch and set the stage for long-term revenue growth.

Cultivating Collaboration for Collective Success

With a staggering 36% of drugs missing their launch forecasts due to limited market access, effective collaboration becomes paramount in the drug commercialization process. In this intricate landscape, where multiple stakeholders—researchers, clinicians, regulatory bodies, and healthcare providers—play crucial roles, seamless communication and collaboration are non-negotiable.

Siloed workflows and communication barriers only add complexity to an already intricate process. However, by fostering a culture of collaboration, pharmaceutical companies can overcome these challenges. Collaboration enables teams to streamline processes, accelerate decision-making, and drive innovation.

Additionally, by integrating data from preclinical trials, clinical research, and regulatory submissions, cross-functional teams can gain holistic insights that inform strategic decisions at every stage of drug development.

Cultivating collaboration as a core value not only enhances efficiency but also fosters a sense of collective ownership, ultimately leading to more successful drug launches and improved patient outcomes.

Embracing Technology for Enhanced Efficiency

Embracing technology isn’t just about staying relevant; it’s about propelling yourself ahead with the force of a thousand engines, and in the realm of drug commercialization, it’s no different.

By leveraging advancements like big data, cloud computing, mobility, and security, companies can supercharge their growth, leaving competitors in the dust. According to a study by Dell, those who invest in such technologies experience up to 53% faster growth rates than their counterparts.

Take, for instance, the drug development process: from research and development to clinical trials and regulatory approval, every stage benefits immensely from streamlined processes and enhanced data management. This allows for faster time-to-market, reduced costs, and ultimately better outcomes for patients. With the right technology in place, companies can revolutionize the way drugs are brought to market, making a significant impact on the industry.

Optimizing Market Access Strategies for Success

At the heart of every successful drug launch lies a well-executed market access strategy. Imagine this: You’ve dedicated years of hard work and billions of dollars to develop a revolutionary pharmaceutical. But what’s the point if patients can’t get their hands on it? Getting your product out there is just as crucial as creating it.

That’s where optimizing market access strategies comes into play. It’s all about making sure your groundbreaking treatment reaches the people who need it most. According to PhRMA, the journey to bring a new drug to market takes around 10 to 15 years. That’s why there needs to be smart, efficient strategies to navigate this process.

By harnessing technology solutions like NetSuite, you can streamline everything from regulatory compliance to distribution, speeding up the journey from lab to patient. With the right market access strategies in place, you can ensure that clinical trial innovations don’t just stay in the lab but make a real difference in people’s lives.

An Agile Solution for Drug Commercialization

Looking ahead to the future of drug commercialization, one agile software solution emerges: NetSuite. Packed with a robust array of features like cloud-based data management, advanced analytics, and collaboration tools, NetSuite empowers pharmaceutical companies to navigate the complexities of commercialization effortlessly. From simplifying regulatory compliance to optimizing supply chain management and more, NetSuite offers a holistic solution for thriving in today’s competitive landscape.

The future of drug commercialization shines brightly, thanks to technology’s transformative potential. By embracing data-driven insights, fostering collaboration, and harnessing innovative solutions like NetSuite, life sciences companies can conquer challenges, foster innovation, and ultimately enhance patient outcomes.

Next Steps

Ready to seize the future of drug commercialization? With the right technology at your fingertips, the opportunities are boundless. Reach out to our industry solution experts today to discover more.

This publication contains general information only and Sikich is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or any other professional advice or services. This publication is not a substitute for such professional advice or services, nor should you use it as a basis for any decision, action or omission that may affect you or your business. Before making any decision, taking any action or omitting an action that may affect you or your business, you should consult a qualified professional advisor. In addition, this publication may contain certain content generated by an artificial intelligence (AI) language model. You acknowledge that Sikich shall not be responsible for any loss sustained by you or any person who relies on this publication.

About the Author